Barostim baroreceptor stimulation improves quality of life in heart failure: 3-year BeAT-HF registry outcomes
Summary
CVRx published 3-year outcomes from the BeAT-HF registry of Barostim patients with heart failure with reduced ejection fraction, showing durable improvements in 6-minute walk distance, NYHA functional class, and quality of life scores (MLHFQ) maintained through 36 months. Hospitalizations were significantly reduced versus matched comparators. The registry expanded on the pivotal BeAT-HF trial demonstrating that baroreceptor stimulation's benefits are maintained and improving over multi-year follow-up.
Why it matters
Three years of durable heart failure improvement from Barostim validates baroreceptor neuromodulation as a true disease-modifying therapy — not merely a symptomatic intervention. The hospitalization reduction data is the strongest possible economic argument for expanded CMS coverage, as heart failure hospitalizations are among the most costly in US healthcare.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial